Meertens, Marinda; Muntinghe-Wagenaar, M. Benthe; Sikkema, Barend J.; Lopez-Yurda, Marta; Retèl, Valesca P.; Paats, Marthe S.; Ter Heine, Rob; Schuuring, Ed; Timens, Wim; Touw, Daan J.; van Boven, Job F.M.; de Langen, Adrianus J.; Hashemi, Sayed M.S.; Hendriks, Lizza E.L.; Croes, Sander; van den Heuvel, Michel M.; Dingemans, Anne Marie C.; Mathijssen, Ron H.J.; Smit, Egbert F.; Huitema, Alwin D.R.; Steeghs, Neeltje; van der Wekken, Anthonie J.
(Frontiers Media S. A., 2023)
BACKGROUND: Alectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed ...